medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2026, Number 2

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2026; 24 (2)

JAK inhibitors as treatment for moderate-to-severe atopic dermatitis: literature review

García-Pineda, Erika-Daniela; García-Romero, Adriana-Dolores

Language: Spanish
References: 46
Page: 260-266
PDF size: 213.74 Kb.


ABSTRACT

This review explores the immunopathogenesis of atopic dermatitis (AD) and the emergence of Janus kinase inhibitors (JAKi) as a cornerstone of modern therapy. As a class of drugs targeting the JAK/STAT signaling pathway, JAKi address the underlying dysregulation responsible for persistent inflammation and pruritus in AD. Their mechanism of action involves the reversible, non-covalent inhibition of JAK enzymes by occupying the catalytic ATP-binding site within the JH1 domain. Current evidence highlights the remarkable efficacy of both topical and oral JAKi in treating moderate-to-severe AD. Furthermore, ongoing research into their long-term safety profiles and molecular specificity is driving a shift toward personalized medicine, allowing for treatments tailored to a patient’s unique genetic and molecular landscape. This review aims to evaluate the clinical utility, mechanism of action, and safety of topical and systemic JAK inhibitors in the management of moderate-to-severe atopic dermatitis.


REFERENCES

  1. Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopicdermatitis. J Allergy Clin Immunol. 2021;148(4):927-940.

  2. Schuler CF 4th, Billi AC, Maverakis E, Tsoi LC, Gudjonsson JE.Novel insights into atopic dermatitis. J Allergy Clin Immunol.2023;151(5):1145-1154.

  3. Huang IH, Chung WH, Wu PC, Chen CB. JAK-STAT signalingpathway in the pathogenesis of atopic dermatitis: An updatedreview. Front Immunol. 2022;13:1068260.

  4. Nakashima C, Yanagihara S, Otsuka A. Innovation in thetreatment of atopic dermatitis: Emerging topical and oral Januskinase inhibitors. Allergol Int. 2022;71(1):40-46.

  5. Nezamololama N, Fieldhouse K, Metzger K, Gooderham M.Emerging systemic JAK inhibitors in the treatment of atopicdermatitis: a review of abrocitinib, baricitinib, and upadacitinib.Drugs Context. 2020;9:2020-8-5.

  6. Sroka-Tomaszewska J, Trzeciak M. Molecular Mechanisms ofAtopic Dermatitis Pathogenesis. Int J Mol Sci. 2021;22(8):4130.

  7. Nutten S. Atopic dermatitis: global epidemiology and riskfactors. Ann Nutr Metab. 2015;66(Suppl 1):8-16.

  8. Krupka-Olek M, Boz·ek A, Aebisher D, Bartusik-Aebisher D,Cies´lar G, Kawczyk-Krupka A. Potential Aspects of the Use ofCytokines in Atopic Dermatitis. Biomedicines. 2024;12(4):867.

  9. Li H, Zhang Z, Zhang H, Guo Y, Yao Z. Update on the Pathogenesisand Therapy of Atopic Dermatitis. Clin Rev Allergy Immunol.2021.

  10. Eichenfield LF, Stripling S, Fung S, et al. Recent Developmentsand Advances in Atopic Dermatitis: A Focus on Epidemiology,Pathophysiology, and Treatment in the Pediatric Setting. PediatrDrugs. 2022;24:293-305.

  11. Tsiogka A, Kyriazopoulou M, Kontochristopoulos G, NicolaidouE, Stratigos A, Rigopoulos D, Gregoriou S. The JAK/STATPathway and Its Selective Inhibition in the Treatment of AtopicDermatitis: A Systematic Review. J Clin Med. 2022;11(15):4431.

  12. Gündüz Ö. JAK/STAT pathway modulation: Does it work inDermatology? Dermatologic Therapy. 2019:e12903.

  13. Damsky W, King BA. JAK inhibitors in dermatology: The promiseof a new drug class. J Am Acad Dermatol. 2017;76(4):736-744.

  14. Rodrigues MA, Torres T. JAK/STAT inhibitors for the treatmentof atopic dermatitis. J Dermatolog Treat. 2019:1-20.

  15. Bieber T. Interleukin-13: Targeting an underestimated cytokinein atopic dermatitis. Allergy. 2019.

  16. Furue M. Regulation of Skin Barrier Function via Competitionbetween AHR Axis versus IL-13/IL-4-JAK-STAT6/STAT3 Axis:Pathogenic and Therapeutic Implications in Atopic Dermatitis.J Clin Med. 2020;9:3741.

  17. Eyerich K, Dimartino V, Cavani A. IL-17 and IL-22 in immunity:Driving protection and pathology. Eur J Immunol. 2017;47(4):607-614.

  18. Morales JK, Falanga YT, Depcrynski A, Fernando J, Ryan JJ.Mast cell homeostasis and the JAK-STAT pathway. GenesImmun. 2010;11(8):599-608.

  19. Chen Q, Cui L, Hu Y, Chen Z, Gao Y, Shi Y. Short-term efficacyand safety of biologics and Janus kinase inhibitors for patientswith atopic dermatitis: A systematic review and meta-analysis.Heliyon. 2023;9(11):e22014.

  20. Gargiulo L, Ibba L, Malagoli P, et al. Management of PatientsAffected by Moderate-to-Severe Atopic Dermatitis with JAKInhibitors in Real-World Clinical Practice: An Italian DelphiConsensus. Dermatol Ther (Heidelb). 2024;14:919-932.

  21. Corbella-Bagot L, Riquelme-McLoughlin C, Morgado-CarrascoD. Long-Term Safety Profile and Off-Label Use of JAKInhibitors in Dermatological Disorders. Actas Dermosifiliogr.2023;114(9):T784-T801.

  22. Serra López-Matencio JM, Morell Baladrón A, Castañeda S.Inhibidores de la vía de señalización JAK-STAT en el tratamientode las enfermedades inmunomediadas. Med Clin. 2018.

  23. Garcia-Melendo C, Cubiró X, Puig L. Inhibidores de JAK: usosen dermatología. Parte 1: generalidades, aplicaciones en vitíligoy en alopecia areata. Actas Dermo-Sifiliográficas. 2020.

  24. Russell MD, Stovin C, Alveyn E, Adeyemi O, Chan CKD, PatelV, Adas MA, Atzeni F, Ng KKH, Rutherford AI, Norton S, CopeAP, Galloway JB. JAK inhibitors and the risk of malignancy: ameta-analysis across disease indications. Ann Rheum Dis.2023;82(8):1059-1067.

  25. Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular andcancer risk with tofacitinib in rheumatoid arthritis. N Engl JMed. 2022;386:316-326.

  26. Bieber T. Atopic dermatitis: an expanding therapeutic pipelinefor a complex disease. Nat Rev Drug Discov. 2022;21(1):21-40.

  27. Bieber T, Thyssen JP, Irvine AD, Tsunemi Y, Chen YF, Sun L,Schloebe A, Riedl E, Cork MJ. Early improvements in signs andsymptoms predict clinical response to baricitinib in patientswith moderate-to-severe atopic dermatitis. Clin Exp Dermatol.2023;48(8):881-888.

  28. Melo A, Carrascosa JM, Torres T. Baricitinib for the treatment ofatopic dermatitis. J Dermatolog Treat. 2022;33(5):2404-2413.

  29. Kim BS, Howell MD, Sun K, Papp K, Nasir A, Kuligowski ME;INCB 18424-206 Study Investigators. Treatment of atopicdermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) ortriamcinolone cream. J Allergy Clin Immunol. 2020;145(2):572-582.

  30. He H, Guttman-Yassky E. JAK Inhibitors for Atopic Dermatitis:An Update. Am J Clin Dermatol. 2018.

  31. Amano W, Nakajima S, Kunugi H, Numata Y, Kitoh A, EgawaG, et al. The Janus kinase inhibitor JTE-052 improves skinbarrier function through suppressing signal transducer andactivator of transcription 3 signaling. J Allergy Clin Immunol.2015;136(3):667-677.

  32. Nakagawa H, Nemoto O, Yamada H, Nagata T, NinomiyaN. Phase 1 studies to assess the safety, tolerability andpharmacokinetics of JTE-052 (a novel Janus kinase inhibitor)ointment in Japanese healthy volunteers and patients withatopic dermatitis. J Dermatol. 2018;45(6):701-709.

  33. Nusbaum K, Fleischer S, Fleischer A Jr. Efficacy of biologics andoral small molecules for atopic dermatitis: A systematic reviewand meta-analysis. J Dermatolog Treat. 2022;33:2534-2544.

  34. Mysler E, Burmester GR, Saffore CD, Liu J, Wegrzyn L, YangC, Betts KA, Wang Y, Irvine AD, Panaccione R. Safety ofUpadacitinib in Immune-Mediated Inflammatory Diseases:Systematic Literature Review of Indirect and Direct TreatmentComparisons of Randomized Controlled Trials. Adv Ther.2024;41(2):567-597.

  35. McLornan DP, Pope JE, Gotlib J, Harrison CN. Current andfuture status of JAK inhibitors. Lancet. 2021;398(10302):803-816.

  36. Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R,Cork M, Bieber T, Thyssen JP, Yosipovitch G, Flohr C, MagnoloN, Maari C, Feeney C, Biswas P, Tatulych S, Valdez H, Rojo R.Efficacy and safety of abrocitinib in adults and adolescentswith moderate-to-severe atopic dermatitis (JADE MONO-1):a multicentre, double-blind, randomized, placebo-controlled,phase 3 trial. Lancet. 2020;396(10246):255-266.

  37. Lé AM, Gooderham M, Torres T. Abrocitinib for the treatment ofatopic dermatitis. Immunotherapy. 2023;15(16):1351-1362.

  38. Armario-Hita JC, Galán-Gutiérrez M, Dodero-Anillo JM,Carrascosa JM, Ruiz-Villaverde R. Updated Review onTreatment of Atopic Dermatitis. J Investig Allergol ClinImmunol. 2023;33(3):158-167.

  39. Munera-Campos M, Carrascosa JM. Janus Kinase Inhibitorsin Atopic Dermatitis: New Perspectives. Actas Dermosifiliogr.2023;114(8):680-707.

  40. Bissonnette R, Maari C, Forman S, Bhatia N, Lee M, Fowler J,Tyring S, Pariser D, Sofen H, Dhawan S, Zook M, Zammit DJ,Usansky H, Denis L, Rao N, Song T, Pavel AB, Guttman-YasskyE. The oral Janus kinase/spleen tyrosine kinase inhibitorASN002 demonstrates efficacy and improves associatedsystemic inflammation in patients with moderate-to-severeatopic dermatitis: results from a randomized double-blindplacebo-controlled study. Br J Dermatol. 2019;181(4):733-742.

  41. Zhao Y, Zhang L, Ding Y, Tao X, Ji C, Dong X, et al. Efficacy andSafety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor,in Patients with Moderate to Severe Atopic Dermatitis: A PhaseII Randomized Clinical Trial. Am J Clin Dermatol. 2021.

  42. K. Characterizing the relationships between patient-reportedoutcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib. J EurAcad Dermatol Venereol. 2022;36(4):602-609.

  43. Martinez-Molina C, Guardiola Tey JM, Ruiz-Ramos J, Feliu A,Puig-Campmany M, Vidal S, et al. Adverse reactions to Januskinase inhibitors: Study of their incidence and predictivefactors in patients with rheumatoid arthritis. Med Clin (Barc).2024;163(9):391-396.

  44. Schuitema A, Anjie SI, van Eeghen AM, Tas SW, LöwenbergM. Symptomatic creatine phosphokinase elevation in aCrohn’s disease patient caused by upadacitinib. Clin Case Rep.2024;12:e8227.

  45. Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R,Cork M, et al. Efficacy and safety of abrocitinib in patients withmoderate-to-severe atopic dermatitis: a randomized clinicaltrial. JAMA Dermatol. 2020;156(8):863-873.

  46. Isufi D, Javanmardi N, Jensen MB, Loft ND, Skov L, ElberlingJ, et al. Risk of dyslipidemia associated with oral Janus kinaseinhibitors: a systematic review and meta-analysis of randomizedplacebo-controlled trials. Int J Dermatol. 2026;65(4):737-745.




2020     |     www.medigraphic.com